Navigation Links
Researchers identify agent responsible for protection against early stages of atherosclerosis
Date:12/12/2011

(Boston) - Researchers from Boston University School of Medicine (BUSM) have identified for the first time the A2b adenosine receptor (A2bAR) as a possible new therapeutic target against atherosclerosis resulting from a diet high in fat and cholesterol. The findings, which appear on-line in Circulation, may have significant public health implications.

Adenosine is a metabolite produced naturally by cells at low levels, and at higher levels during exercise or stress. Adenosine binds to and activates cell surface receptors, one of which is the A2bAR. Previous studies have described the A2bAR as anti-inflammatory and protective against kidney ischemia, cardiac reperfusion injury and restenosis, typically via bone marrow cell signals.

In mouse models, BUSM researchers found atherosclerosis induced by a high-fat diet was more pronounced in the absence of the A2bAR. They also found bone marrow transplantation experiments indicated that A2bAR bone marrow cell signals alone were not sufficient to elicit this effect. "A2bAR genetic ablation led to elevated levels of liver and plasma cholesterol and triglycerides, and to fatty-liver pathology typical of steatosis, assessed by enzymatic assays and analysis of liver sections," explained senior author Katya Ravid, MD, a professor of medicine and biochemistry at BUSM.

The researchers also identified the mechanism underlying this effect in the liver, involving the control of the transcription factor SREBP-1 and its downstream targets-regulators of lipid synthesis. They found restoration of the A2bAR in the liver of A2bAR null mice reduced the lipid profile and atherosclerosis. "Most importantly, in vivo administration of a pharmacological activator of the A2bAR in control mice on a high fat diet reduced lipid profile and atherosclerosis. Thus, this study provides the first evidence that the A2bAR regulates liver hyperlipidemia and atherosclerosis, suggesting that this receptor may be an effective therapeutic target against earlier stages of atherosclerosis," Ravid added.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers use new finding to clear bloodstream malaria infection in mice
2. Penn researchers repair immune system in leukemia patients following chemotherapy
3. Scar findings could lead to new therapies, Stanford researchers say
4. Researchers identify a novel therapeutic approach for liver cancer
5. Researchers design Alzheimers antibodies
6. Toronto researchers obtain detailed molecular signature for Tankyrase
7. Danish mushroom inspires cancer researchers
8. Bone Drugs May Also Battle Breast Cancer, Researchers Say
9. Researchers discover that changes in bioelectric signals cause tadpoles to grow eyes in back, tail
10. UCLA researchers suggest unconventional approach to control HIV epidemics
11. Mayo Clinic researchers find drug duo kills chemotherapy-resistant ovarian cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... herbal-based and non-steroidal skincare products, was awarded as winners of American Dreams & ... This competition was hosted jointly by HSN and Good Housekeeping. , Steven ...
(Date:3/23/2017)... VA (PRWEB) , ... March ... ... Evaluation Reports: Complying with European Guidelines and the New MEDDEV 2.7/1 Rev. ... 3:00 p.m. ET, http://www.fdanews.com/mdclineval                  , How will the new EU ...
(Date:3/23/2017)... ... March 23, 2017 , ... GeBBS Healthcare Solutions unveils the ... 21st annual Compliance Institute on March 26-28 in National Harbor, Maryland. ... chart types with a comprehensive set of features including built-in workflow, interactive audit ...
(Date:3/23/2017)... ... ... “Beyond and Back”: a true-life testimony of tragedy and the miraculous power ... Rose, a wife, mother and grandmother committed to sharing her many spiritual adventures which ... new book presents actual events in the life of her family, which validate her ...
(Date:3/23/2017)... ... March 23, 2017 , ... “My Journey Through Heaven”: the true-life ... infinitely more profound faith of God’s promise of Heaven for His people. “My Journey ... each day with his wife, three children and six grandchildren living and doing for ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") ... is pleased to announce that its majority-owned subsidiary, ... U.S. Food and Drug Administration (FDA) for the ... tablets in the 12.5 mg and 25 mg ... equivalent of the branded product Xenazine ® ...
(Date:3/23/2017)... , March 23, 2017 ReNeuron ... its CTX cells in chronic stroke patients, despite not meeting ... primary outcome measure, the Action Research Arm Test (ARAT). As ... to a pivotal controlled clinical study in 2017. Beyond CTX, ... (RP) trial in 2017 and Phase I data from its ...
(Date:3/23/2017)... 2017 The Board of Directors of NeuroVive ... Meeting, which is to take place on Thursday, April 27, 2017, ... Lund, Sweden . ... Please see the attached notification, which is being announced within ... NeuroVive Pharmaceutical AB (Publ) The Board Of Directors About ...
Breaking Medicine Technology: